Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vistin Pharma ASA's revenue per share for the
three
months ended in Mar. 2026 was kr2.53.
Vistin Pharma ASA's revenue per share for the trailing twelve months (TTM) ended in Mar. 2026 was kr10.13.
Warning Sign:
Vistin Pharma ASA revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Vistin Pharma ASA was 1.90% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 16.30% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 14.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Vistin Pharma ASA's Revenue per Share or its related term are showing as below:
LTS:0RAM'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -20.8 Med: 5.4 Max: 19.8
Current: 16.3
During the past 13 years, Vistin Pharma ASA's highest 3-Year average Revenue Per Share Growth Rate was 19.80% per year. The lowest was -20.80% per year. And the median was 5.40% per year.
LTS:0RAM's 3-Year Revenue Growth Rate is ranked better than 83.02% of 901
companies
in the Drug Manufacturers industry
Industry Median: 3.9
vs LTS:0RAM: 16.30
Vistin Pharma ASA (LTS:0RAM) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Vistin Pharma ASA Revenue per Share Related Terms
Vistin Pharma ASA Revenue per Share Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAM vs ZTS, UTHR, VTRS: Revenue per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's PS Ratio distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Vistin Pharma ASA's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr10.13
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistin Pharma ASA (LTS:0RAM) has a Revenue per Share of kr10.13 as of Mar. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Vistin Pharma ASA and its competitors. According to the industry distribution chart, Vistin Pharma ASA ranks #153 out of 901 companies in the Drug Manufacturers industry, placing it in the top 17%.
Is Vistin Pharma ASA's Revenue per Share too high?
Vistin Pharma ASA's current Revenue per Share is kr10.13. Based on the distribution chart, Vistin Pharma ASA ranks #153 out of 901 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vistin Pharma ASA has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Revenue per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #153 out of 901 companies for Revenue per Share. This places Vistin Pharma ASA in the top 17% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 3.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Drug Manufacturers company?
The median Revenue per Share among Drug Manufacturers companies is 3.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Revenue per Share is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Revenue per Share is kr10.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.76, compared to a current price of kr20.40 — trading 20.8% below its estimated fair value. The current Revenue per Share is kr10.13. Vistin Pharma ASA's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Revenue per Share is kr10.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.40 is trading 20.8% below its estimated GF Value™ of kr25.76.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
Revenue per Share: kr10.13
GF Value™: kr25.76 vs. price of kr20.40 (20.8% below fair value)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
75GF Score
Get the complete analysis for LTS:0RAM
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
